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Divergent roles of interferon-γ and 
innate lymphoid cells in innate and 
adaptive immune cell-Mediated 
intestinal inflammation
Jennifer Brasseit, Cheong K. C. Kwong Chung, Mario Noti, Daniel Zysset, Nina Hoheisel-
Dickgreber, Vera Genitsch, Nadia Corazza and Christoph Mueller*
Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland
Aberrant interferon gamma (IFNγ) expression is associated with the pathogenesis of 
numerous autoimmune- and inflammatory disorders, including inflammatory bowel dis-
eases (IBD). However, the requirement of IFNγ for the pathogenesis of chronic intestinal 
inflammation remains controversial. The aim of this study was thus to investigate the 
role of IFNγ in experimental mouse models of innate and adaptive immune cell-medi-
ated intestinal inflammation using genetically and microbiota-stabilized hosts. While we 
find that IFNγ drives acute intestinal inflammation in the anti-CD40 colitis model in an 
innate lymphoid cell (ILC)-dependent manner, IFNγ secreted by both transferred CD4 
T cells and/or cells of the lymphopenic Rag1−/− recipient mice was dispensable for CD4 
T cell-mediated colitis. In the absence of IFNγ, intestinal inflammation in CD4 T cell recip-
ient mice was associated with enhanced IL17 responses; consequently, targeting IL17 
signaling in IFNγ-deficient mice reduced T cell-mediated colitis. Intriguingly, in contrast 
to the anti-CD40 model of colitis, depletion of ILC in the Rag1−/− recipients of colitogenic 
CD4 T cells did not prevent induction of colonic inflammation. Together, our findings 
demonstrate that IFNγ represents an essential, or a redundant, pro-inflammatory cyto-
kine for the induction of intestinal inflammation, depending on the experimental mouse 
model used and on the nature of the critical disease inducing immune cell populations 
involved.
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inTrODUcTiOn
Inflammatory bowel diseases (IBD) comprise two distinct entities, ulcerative colitis (UC) and Crohn’s 
disease (CD), that are characterized by chronic relapsing intestinal inflammation in genetically 
susceptible individuals (1). Recent genome wide association studies in IBD patients have elucidated 
distinct genetic defects, which contribute to uncontrolled inflammatory responses and changes in 
the gut microbiome. The use of animal models has been indispensable in deciphering the complex 
pathophysiology underlying IBD and in the design of several approved compounds for the treat-
ment of IBD. The therapeutic armamentarium for IBD is constantly growing with anti-TNF agents 
being at present the treatment of choice, particularly in patients with steroid-resistant IBD. However, 
around 10–30% of IBD patients do not respond to TNF targeting strategies or lose responsiveness 
with progression of disease. Therefore, a better understanding of the complex immune pathways 
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underlying IBD pathogenesis is mandatory to develop new 
effective treatment modalities for patients who are refractory to 
current treatment protocols.
Among the pro-inflammatory cytokines driving intestinal 
inflammation, interferon gamma (IFNγ) has been shown to be 
highly expressed in the affected mucosa of CD patients and to 
be one of the main drivers of intestinal inflammation in distinct 
animal colitis models (2). Therefore, it has been proposed that 
blocking IFNγ should have beneficial effects on the development 
of colitis. In line with this hypothesis, blockade of IFNγ during 
T cell transfer model of colitis in Scid mice was shown to amelio-
rate intestinal inflammation (3). Similarly, IFNγ-deficient mice 
were protected from DSS-induced colitis (4), and in the innate 
lymphoid cell (ILC) dependent anti-CD40-induced colitis (5, 6). 
While these studies suggested a fundamental role for IFNγ in 
the pathogenesis of intestinal inflammation, other studies have 
reported that DSS-induced colitis was not significantly affected 
by neutralizing IFNγ (7) and IFNγ-deficient mice developed 
2,4,6-trinitrobenzen sulfonic acid induced colitis to a similar 
extent as wild-type mice. In humans, therapeutic approaches to 
target IFNγ signaling in IBD patients have shown limited efficacy 
suggesting that other pro-inflammatory mediators may compen-
sate for reduced IFNγ responses to drive intestinal inflammation 
(8).
The inability to ameliorate colitis by inhibiting IFNγ has been 
attributed to the emergence of pro-inflammatory Th17  cells 
(9). Whereas Th17 cells are important players in the protection 
against extracellular and intracellular microbial pathogens 
such as Candida albicans and Salmonella typhimurium by 
recruiting neutrophils and activating intestinal epithelial cells 
(10), elevated IL17A levels have been implicated in intestinal 
inflammation (11, 12). Accordingly, transfer of T cells deficient 
in RORγt, i.e., the immune cell-specific isoform of RORγ, which 
is the key transcription factor of Th17 cells in both humans and 
mice (13), prevented the induction of colitis (14) and numer-
ous studies have shown that IL23, which promotes Th17  cell 
differentiation, is required for the development of IBD (15, 16). 
Hence, Th17 cells are considered to be critical effector cells in 
the development of IBD. Although Th17 cells represent a dis-
tinct lineage of CD4 helper T cells, a developmental plasticity of 
Th17 cell subsets has recently been demonstrated implying that 
Th17 cells can diverge to acquire Th1-like features through the 
co-expression of IFNγ (17). This transition of Th17 precursors 
to Th1-like cells was absolutely required for colitis development, 
as IFNγ-deficient Th17 cells failed to induce intestinal inflam-
mation (17).
Taken together, while IFNγ has been demonstrated to be 
highly expressed in CD patients as well as in several animal 
models of colitis, it remains controversial whether IFNγ plays an 
indispensable role in the pathogenesis of IBD. The discrepancy 
regarding the relevance and source of IFNγ for the development 
of colitis can be attributed to the animal models of colitis used 
(notably, innate vs. adaptive immune driven colitis, acute vs. 
chronic models), differences in the hygiene status, and the com-
position of the intestinal microbiota in the different animal facili-
ties. To specifically address these issues, we aimed to investigate 
the role of IFNγ in two frequently used models of colitis (innate 
vs. adaptive immune driven colitis models), using genetically and 
microbiota-stabilized hosts.
resUlTs
Divergent roles of iFnγ in innate and 
adaptive immune cell-Mediated Models of 
intestinal inflammation
IFNγ is a prototypic pro-inflammatory cytokine with pleiotropic 
functions. Although IFNγ has been associated with IBD and 
experimental models of intestinal inflammation, its role in dis-
ease pathogenesis remains controversial. Such controversies may 
be the result of the mode of disease induction, distinct disease 
kinetics, genetic background, or variability in the gut commensal 
community structure in the different vivaria (18, 19). Here, we 
tested the role for IFNγ in two well-established models of intestinal 
inflammation in microbiota-stabilized hosts. Employing a model 
of innate-mediated intestinal inflammation, we first assessed 
the role of IFNγ in lymphopenic mice in response to anti-CD40 
stimulation. While anti-CD40 treated Rag1−/− IFNγ-sufficient 
mice developed wasting disease and clinical signs of intestinal 
inflammation as assessed by a histopathological score, Rag1−/− 
Ifng−/− mice were protected from anti-CD40-induced weight loss 
and acute intestinal inflammation (Figures  1A–C). Consistent 
with previous report (20), the main source of IFNγ in this innate 
model of acute intestinal inflammation was mostly likely to be 
derived from group 3 innate lymphoid cells (ILC3) since target-
ing ILC3 responses by means of antibody depletion (anti-Thy1.2) 
or employing genetic models that lack ILC3 (Rag2−/− RorcGFP/
GFP) ameliorated colitis (Figures 1A–C). This suggests that ILC3 
intrinsic IFNγ-production was sufficient for induction of acute 
intestinal inflammation in the anti-CD40 innate colitis model. 
Given the importance for IFNγ and ILC3 in innate immune cell-
mediated acute intestinal inflammation, we next assessed their role 
in the CD4 T cell transfer model of colitis. To this end, naive CD4 
CD45RBhi T cells from IFNγ-sufficient (Ifng+/+) or IFNγ-deficient 
mice (Ifng−/−) were adoptively transferred into lymphopenic IFNγ 
sufficient (Rag1−/− Ifng+/+) or deficient hosts (Rag1−/− Ifng−/−). CD4 
T cell expansion in peripheral blood as a sign of colitis onset (19) 
and body weight were monitored throughout the experiment. 
Both, IFNγ-sufficient and -deficient mice developed comparable 
histopathological changes in the colonic mucosa in response to 
adaptive CD4 T cell transfers associated with 10–15% weight loss 
of initial body weight (Figures 1D–F). Interestingly, the analysis 
of the distinct histopathological subscores revealed a statistically 
significant attenuation of goblet cell loss in the complete absence 
of IFNγ secretion when compared to those experimental groups 
where either transferred cells and/or recipient cells were capable 
of secreting IFNγ (data not shown). When either colitogenic 
Ifng−/− CD4 T cells were transferred into Ifng+/+ Rag1−/− recipients, 
or upon transfer of colitogenic Ifng+/+ CD4 T  cells into Ifng-/-
Rag1−/− recipients comparable kinetics of weight loss and extent 
of histopathological alterations to those shown in Figures 1D–F 
were seen (data not shown).
While ILC3 promoted the pathogenesis of anti-CD40-induced 
innate colitis, targeted manipulation of ILC3 in the CD4 T cell 
FigUre 1 | IFNγ is critical for induction of innate αCD40, but not for CD4 T cell-mediated colitis. (a–c) Lymphopenic mice were injected with anti-CD40 antibodies 
or (D–F) transferred with colitogenic T cells to induce colitis. (a,D) Body weight and (B,e) histopathological scores of Rag1−/−, Rag1−/− Ifng−/−, Rag1−/− mice that 
were αThy1.2 treated and Rag2−/−RorcGFP/GFP mice after colitis induction. (c,F) Representative hematoxylin and eosin staining of colonic tissue sections from mice 
during active phase of colitis. Scale bars indicate 100 µm. Symbols indicate mean ± SD (a,D) and individual mice (B,e) of three independent experiments. P-values 
were determined using one-way ANOVA with Dunn’s multiple comparison test in (a): Black symbols P-values for Rag1−/−Ifng+/+ vs. Rag2−/− RorcGFP/GFP; red symbols: 
Rag1−/− Ifng+/+ compared with Rag1−/− Ifng−/− and Rag1−/− + αThy1.2, *P < 0.05; **P < 0.01; ***P < 0.001. P-values ≥ 0.05 not shown.
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transfer colitis model did not alter disease outcome. Indeed, trans-
fer of colitogenic T cells into congenic Rag1−/− mice depleted of 
ILC by means of anti-Thy1.2 antibodies or into Rag2−/− RorcGFP/GFP 
mice that lack ILC3 resulted in weight loss and intestinal inflam-
mation to similar extent (anti-Thy-1.2 treated), or even more 
severe histopathological signs (Rag2−/− RorcGFP/GFP recipient 
mice) as observed in T  cell-transferred control Rag1−/− mice 
(Figures 1D–F).
Taken together, we demonstrate that depending on the mode 
of colitis induction, IFNγ is critical for disease induction in 
the innate anti-CD40 mediated colitis model, whereas IFNγ 
production is dispensable in the CD4 T cell-dependent transfer 
colitis. Intriguingly, the strict IFNγ dependent colitis induction 
in the anti-CD40 colitis model in Rag1−/− mice is also associated 
with a strict dependence on ILC as inducers of colitis while in 
the presence of colitogenic CD4 T cells ILC and IFNγ are not 
critical for the induction and progression of CD4 T cell transfer 
colitis.
absence of iFnγ Favors il17a Production 
by colitogenic cD4 T cells in the colon of 
Rag1−/− recipient Mice
Th1 and Th17 immune cells were previously shown to cooperate 
in the development of colitis (17). Since CD4 T  cell-induced 
colitis develops in the absence of IFNγ (Figures 1D,E), we thus 
assessed the pro-inflammatory cytokine profile of colitogenic 
CD4 T cells in the presence or absence of IFNγ. For this purpose, 
colitis was induced in Rag1−/− Ifng+/+ or Rag1−/− Ifng−/− mice by 
adoptive transfer of IFNγ-sufficient or -deficient CD4 CD45RBhi 
T cells. Upon occurrence of clinical signs of colitis (see Materials 
and Methods for details), CD4 T  cells were isolated from the 
colonic lamina propria (LP) for subsequent analysis of cytokine 
responses. Interestingly, in the complete absence of IFNγ, i.e., 
when neither host cells nor transferred CD4 T cells are able to 
produce IFNγ, we observed increased frequencies and total num-
bers of IL17A producing colonic CD4 T cells (Figures 2A–D). 
FigUre 2 | In the absence of IFNγ frequencies and numbers of IL17A producing colonic CD4 T cells are dramatically increased in colitic mice. Cytokine expression 
analysis of colonic lamina propria (LP) CD4 T cells, PMA/ionomycin-stimulated in the presence or absence of IFNγ. Colonic LP cells were isolated during active 
colitis (24–26 days post transfer of colitogenic Ifng+/+, and Ifng−/− CD4 CD45RBhi T cells into Rag1−/−, and Rag1−/− Ifng−/− recipient mice, respectively). (a,B) 
Representative FACS blots showing IFNγ, IL17A, or TNFα expression of CD4 T cells. (c) Relative cell frequencies and (D) absolute cell numbers of cytokine 
expressing CD4 T cells. Bars indicate mean ± SD from three independent experiments with n = 5–9 mice per group. P-value was determined using the two-tailed 
Mann–Whitney test with *P < 0.05; **P < 0.01; ***P < 0.001. CD4 T cells were identified as live, single, CD45+ leukocytes, autofluorescent negative, and CD4 CD3 
T cells.
4
Brasseit et al. IFNγ: Divergent Roles in Colitis
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 23
In contrast, no changes in TNFα cytokine production were 
observed irrespective of whether the host, and/or transferred 
CD4 T cells were deficient in IFNγ-expression (Figures 2A–D). 
Intriguingly, in the presence of host-derived IFNγ-secreting cells 
(in Ifnγ +/+ Rag1−/− recipients), the differentiation of the trans-
ferred Ifnγ−/− CD4 T cells into IL17A-producing CD4 T cells is 
attenuated when compared to Ifnγ −/− CD4 T  cells transferred 
into Ifnγ−/− Rag1−/− recipient mice. The differential conversion 
into IL17A-producing CD4 T cells, however, did not affect the 
severity, or the kinetics of colitis induction (data not shown).
iFnγ negatively regulates Th17 
Polarization In Vitro
The observation that in the absence of IFNγ signaling colitogenic 
CD4 T  cells preferentially produce IL17A (Figures  2A–D), 
prompted us to assess whether IFNγ can impede Th17 polariza-
tion using an in vitro culture system. To this end, sort-purified 
CD4 CD45RBhi T cells derived from Ifnγ-sufficient or -deficient 
hosts were cultured in  vitro under Th17 priming conditions 
(rmIL6 (40  ng/ml), rhTGFβ (6  ng/ml), rmIL23 (20  ng/ml) in 
FigUre 3 | IFNγ inhibits differentiation of naïve CD4 CD45RBhi T cells into Th17 cells in vitro. Naïve splenic CD4 CD45RBhi T cells from Ifng+/+ or Ifng−/− mice were 
cultured for 8 days under Th17 priming conditions. Cells were restimulated with PMA/ionomycin and stained intracellularly for cytokines. (a) Representative FACS 
blots of the Th17 primed CD4 T cells from Ifng+/+ or Ifng−/− mice in the presence (adding recombinant mouse IFNγ) or absence of IFNγ (anti-IFNγ neutralizing 
antibodies). (B) Relative frequencies of cytokine positive Th17 primed CD4 T cells. Bars indicate mean ± SD from pooled data from three independent experiments 
with n = 3–6 duplicate values per treatment group. P-value was determined using one-way ANOVA with Dunn’s multiple comparison test with *P < 0.05; **P < 0.01. 
CD4 T cells were identified as live, single, CD45 leukocytes, autofluorescent negative, and CD4 CD3 T cells.
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the presence of neutralizing anti-IL4 (10 µg/ml), and anti-IFNγ 
(20  µg/ml)) on anti-CD3/anti-CD28 coated plates (1  mg/
ml) as previously reported (21) with, or without, recombinant 
IFNγ. Importantly, IFNγ-sufficient and -deficient CD4 T  cells 
produced comparable amounts of IL17A under Th17 priming 
conditions demonstrating the capacity of naïve CD4 T cells to 
differentiate into Th17 cells irrespective of T cell intrinsic IFNγ 
(Figures 3A,B). Critically, exogenous administration of IFNγ to 
Th17 priming culture conditions significantly reduced the fre-
quencies of IL17A producing CD4 T cells in both IFNγ-sufficient 
and -deficient CD4 T  cells (Figures  3A,B). In summary, we 
demonstrate that IFNγ negatively regulates CD4 Th17  cell 
polarization in vitro irrespective of the intrinsic capacity of CD4 
T cells to produce IFNγ.
absence of iFnγ shifts the gene 
expression Profile from a Th1-, to a Th17 
cell-like signature in colitic cD4 T cell-
Transferred Rag1−/− Mice
To test whether absence of IFNγ signaling alters colonic gene 
expression toward a Th17 cell-like immune profile, we compared 
mRNA expression levels for Th1 and Th17 related genes in the 
inflamed colonic mucosa of Ifnγ-sufficient, vs. Ifnγ-deficient 
mice. While induction of transfer colitis in Ifnγ-sufficient mice 
(Ifng+/+ CD4 T cells → Rag1−/− Ifng+/+ mice) resulted in elevated 
expression of the Ifnγ-associated genes Cxcl9 and Cxcl10 in the 
colon (Figure 4), absence of IFNγ (Ifng−/− CD4 T cells → Rag1−/− 
Ifng−/− mice) significantly favored the expression of Th17 related 
genes including Il17a, Il17f, Il22, Ccl20, and Rorgt (Figure  4). 
Interestingly, while we found a significant shift in the expression 
of Th1 vs. Th17 associated genes in absence of IFNγ signaling, 
other genes encoding pro-inflammatory mediators including 
Il6, Gmcsf, Il23p19, and Tnf were expressed at similar magni-
tudes, showing that IFNγ specifically blocks Th17-related gene 
expression.
Collectively, our findings suggest that IFNγ contributes to 
colonic inflammation but its absence does not prevent T  cell 
transfer colitis. Given that in the absence of IFNγ, CD4 T cells 
acquire a Th17-like phenotype, exaggerated IL17 immune 
responses may therefore compensate for the lack of IFNγ.
Targeting excessive il17 responses in 
iFnγ-Deficient hosts reduces colonic 
inflammation
Since CD4 T cell-mediated colitis develops in the absence of IFNγ 
production and in the absence of IFNγ the CD4 T cells prefer-
entially differentiate into Th17-like cells, we next investigated 
whether neutralization of excessive IL17 responses in the absence 
FigUre 4 | Absence of IFNγ shifts the gene expression profile in the affected colon from a Th1-, to a Th17-like signature in CD4 T cell-transferred Rag1−/− mice. 
mRNA expression levels of the indicated genes of whole colonic tissue of Rag1−/− Ifng+/+ mice transferred with Ifng+/+ colitogenic T cells or Rag1−/− Ifng−/− mice 
transferred with Ifng−/− colitogenic T cells 24–26 days post transfer. Bars indicate mean ± SD from three independent experiments with n = 5–8 mice per group. 
P-value was determined using the two-tailed Mann–Whitney test with *P < 0.05; **P < 0.01; ***P < 0.001.
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of IFNγ attenuates colonic inflammation. Therefore, Ifng−/− CD4 
CD45RBhi T cells were transferred into Rag1−/− Ifng−/− mice for 
colitis induction and recipient mice were treated with either 
isotype control antibody or neutralizing antibodies against IL17A 
and against IL17F twice a week for the duration of the experiment. 
In the complete absence of IFNγ administration of anti-IL17A/F 
mAb’s resulted in a significantly attenuated histopathological 
score, associated with a significantly reduced weight loss compared 
to control treated mice (Figures 5A–C). The attenuated weight 
loss was associated with significantly reduced serum levels of the 
pro-inflammatory mediators TNFα, IL1β, and IL6 (Figure 5D). 
A similar trend for decreased pro-inflammatory mediators in 
anti-IL17A/F-treated recipients was also detected in the colonic 
homogenates, although these differences were not statistically 
significant (data not shown). In contrast, when IL17A and IL17F 
were neutralized in the presence of IFNγ-producing cells, the 
histopathological assessment revealed severe colitis although the 
total score was slightly lower in anti-IL17A and IL17F treated 
mice compared to untreated recipient mice (data not shown). 
Importantly, in response to IL17A/F neutralization, no changes 
in the frequencies of colonic CD4 T cells nor alterations in their 
capacity to produce IL17A and TNFα were observed, indicating 
that the anti-IL17A/F treatment does not lead to a depletion of 
IL17A/F sufficient CD4 T cells (Figures 5E,F).
Collectively, we demonstrate that targeting exacerbated IL17 
secretion in an IFNγ-deficient environment has disease-limiting 
properties in the CD4 T cell transfer mouse model of colitis. These 
findings may be of clinical importance as combinatorial therapies 
targeting IFNγ together with IL17A/F may have disease-limiting 
effects also in patients with IBD.
DiscUssiOn
The use of experimental models of colitis has critically influ-
enced our understanding of complex immunological processes 
that mediate the pathogenesis of IBD. In the present study, we 
strengthen the observations of the differential role of IFNγ dur-
ing innate vs. adaptive murine models of colitis. The importance 
of IFNγ for the development of colitis has been investigated for 
many years with controversial results. IFNγ has been shown to 
be elevated in the colonic mucosa of IBD patients as well as in 
several animal model of colitis (2, 22) and the beneficial effect of 
IFNγ neutralizing antibodies in T cell dependent animal models 
of colitis indicated the importance of this cytokine for colitis 
FigUre 5 | Neutralization of IL17A and IL 17F attenuates exacerbating CD4 T cell-induced colitis in the absence of IFNγ. Rag1−/− Ifng−/− mice were transferred with 
Ifng−/− CD4 CD45RBhi T cells and treated with anti-IL17A and anti-IL17F neutralizing antibodies, or isotype control (250 μg/mouse) twice a week. (a) Body weight 
during colitis induction and (B) histopathological scores. (c) Representative hematoxylin and eosin staining of colonic tissue sections from mice during active phase 
of colitis. Scale bars indicate 100 µm. (D) Serum level for TNFα, IL6, and IL1β. Cells were isolated from colitic mice from the colonic lamina propria (col LP), 
mesenteric lymph nodes (MLN), caudal lymph node (CLN) and spleen, restimulated with PMA/ionomycin for subsequent intracellular FACS analysis. Relative cell 
frequencies of (e) CD4 T cells and (F) cytokine expressing CD4 T cells are shown in experimental mice treated, with, and without, anti-IL17A/IL17F mAb’s. CD4 
T cells were identified as single, live, autofluorescent negative, CD45 leukocytes, positive for CD4 and CD3. P-values were determined using the two-tailed 
Mann–Whitney test with *P < 0.05; **P < 0.01; ***P < 0.001.
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induction (3). These observations were also supported by the 
fact that T-bet-deficient T cells failed to induce colitis in adoptive 
T cell transfer experiments. This outcome was mainly related to 
T-bet-dependent induction of Th1 cytokine production, as trans-
ferred T-bet-deficient CD4 T cells produced low amounts of IFNγ 
(23). Nonetheless, contradictory results concerning the relevance 
and source of IFNγ in the development of colitis have also been 
reported. Simpson et al. demonstrated that IFNγ expression by 
T  cells was not necessary for the development of colitis after 
adoptive transfer (24). Similarly, the use of IFNγ neutralizing 
antibodies in IBD patients seems to be inefficient or only partially 
beneficial for clinical improvement questioning the role of IFNγ 
in the pathogenesis of IBD (8).
Here, we demonstrated a divergent role of IFNγ in the devel-
opment of colitis. The presence of IFNγ is a prerequisite in the 
anti-CD40 model of colitis whereas by using the T cell transfer 
model of colitis we clearly demonstrate that IFNγ is not necessary 
for the development of colitis as mice developed disease in the 
complete absence of IFNγ. Colitis induction in the absence of 
IFNγ-producing T cells is preferentially driven by Th17-related 
mediators including IL17A and IL17F. Inhibition of IL17A and 
IL17F in the absence of IFNγ partially protected mice from devel-
oping intestinal disease. In contrast, when IL17A and IL17F were 
neutralized in the presence of IFNγ-producing cells minimal 
effect on weight loss or histopathological scores was observed 
indicating that inhibition of Th17 cytokine per se is not sufficient 
for the protection of colitis induction (data not shown).
The contribution of IL17A/F to the pathogenesis of chronic 
intestinal inflammatory disorders has been investigated in several 
animal models with conflicting results. On one hand, disease 
promoting effects in mouse models of colitis were ascribed to 
IL17A/F-mediated signaling as blocking IL17A and IL17F ame-
liorated disease (14, 25). In support of our findings, IL17-driven 
responses were exacerbated in the absence of the transcription 
factor T-bet, which commits CD4 T cells to the Th1 lineage (26). 
On the other hand, protective effects of IL17A were ascribed to 
an IL17A-mediated attenuation of T-bet and IFNγ expression, 
leading to a more aggressive colitis upon transfer of IL17A−/− CD4 
T  cells into lymphopenic hosts (27). Furthermore, anti-IL17A 
treatment failed to attenuate colitis induced by adoptive transfer 
of Tbx21−/− CD4 T  cells in Rag1−/− recipients (28). IL17A also 
enhances intestinal barrier functions by counteracting IFNγ-
triggered intestinal epithelial permeability (29, 30).
The findings of a disease-attenuating effect of IL17A in some, 
but not all, mouse models of colitis is also reflected in human 
studies that showed exacerbation of intestinal inflammation in 
IBD patients treated with IL17 targeting biologicals (31, 32). 
Although in the present study, we primarily aimed to assess the 
precise impact of IFNγ rather than IL17 on the development of 
colitis in two separate mouse models, our results support the idea 
that IL17 compensates for the absence of T  cell-derived IFNγ 
to drive colitis induction, suggesting that both the IFNγ- and 
IL17-mediated effects are targeted to attenuate chronic intestinal 
inflammation. In support of this, it has been reported that IL17A 
blockade by Secukinumab (AIN457) is ineffective in CD patients 
with higher rates of adverse events observed in these patients 
compared with placebo group (31). In addition, phase II trials 
with Ustekinumab which blocks the p40 subunit of IL12 (which 
is required for Th1 cell development) and IL23 (which is required 
for the maintenance of Th17 cells) has shown beneficial effects in 
CD patients (33). Of note, the use of the dihydroorotate dehy-
drogenase inhibitor Vidofludimus (SC12267) which attenuates 
IL17A/F and IFNγ, is also in clinical trials and it remains to be 
seen whether it has the potential of becoming useful treatment 
modalities in IBD patients (34).
The observation that both IFNγ and IL17 responses alone can 
induce colitis (in a T cell dependent model) raised the question 
of whether there is a “division of labor” between Th1 and Th17 
responses in promoting intestinal inflammation or whether Th1 
can regulate Th17 responses and vice versa. Our findings show that 
IFNγ antagonizes IL17 responses, and absence of IFNγ results in 
a predominant IL17-driven immune response that is sufficient to 
induce colitis. This is in agreement with previous report showing 
that absence of T-bet results in an exacerbated Th17 response 
due to the increased responsiveness of T-bet−/− CD4 T  cells to 
IL-23 (26). The IFNγ-mediated downregulation of IL17 immune 
response may occur through the inhibition of Stat3 and Rorγt 
transcription factor (21). This suppression has also been further 
emphasized in other disease models where IFNγ blockade even 
led to an exacerbation of disease by increasing Th17 immune 
responses, e.g., in experimental autoimmune encephalomyelitis, 
collagen-induced arthritis, or experimental autoimmune uveitis 
(35–37).
Recent reports demonstrated that Th17  cells retain late 
developmental plasticity and have the ability to divert into Th1-
like features (17). Consequently in addition to the production 
of IL17A and IL17F, Th17 also can produce IFNγ. Importantly, 
while in  vitro differentiated IFNγ expressing Th17  cells can 
induce colitis after adoptive transfer, in  vitro IFNγ -deficient 
Th17 cells (still expressing IL17) are unable to induce disease in 
recipients (17). In this model, development of disease required 
the transition of a subset of Th17 precursors into Th1-like cells. 
Moreover in the same report, they demonstrated that Th17 cells, 
which are unable to produce IFNγ, supported the de novo dif-
ferentiation of Rorγt deficient naïve CD4 CD45RBhi T cells into 
pathogenic IFNγ producing Th1 cells. Single transfer of either 
Rorγt deficient naïve CD4 CD45RBhi or IFNγ-deficient Th17 
T  cells did not induce disease, pointing to a principal role of 
IFNγ for colitis development. Our results are in contrast with this 
model since in our hands CD4 T cell transfer colitis is induced 
even in the absence of IFNγ. Taken together, this suggests that 
while IFNγ expression by Th17 T cells is a prerequisite for colitis 
induction when the cells were functionally polarized in  vitro 
before colitis induction, in vivo priming of naïve T cell into Th17 
T cells is sufficient for colitis induction and does not require the 
presence of IFNγ. This is in line with a report by Shen et al. who 
demonstrated that optimal CD4 T cell priming in the selective 
environment in vitro will lead to a strong polarization of CD4 
T cells with limited functional plasticity, whereas in vivo, naïve 
CD4 T cells will retain their functional plasticity and diversity 
upon transfer in lymphopenic recipients (38). The differential 
mode of CD4 T  cell priming may thus explain some of the 
observed discrepancies with regard to the role of IFNγ and/or 
IL17 in colitis induction.
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Recent progress in the understanding of the pathogenesis of 
chronic intestinal inflammation in mouse models and patients 
with IBD revealed important contribution from myeloid and 
lymphoid innate immune cells to the onset of intestinal inflam-
mation. In particular, ILC have emerged as key players in mucosal 
immunity by producing large amounts of pro-inflammatory 
cytokines such as IL17, IL22, and IFNγ. Their role in driving 
intestinal inflammation has been described in several colitis 
models (5, 39). Nevertheless, using the transfer model of colitis we 
demonstrated that ILC depleted recipient and Rag2−/− RorcGFP/GFP 
mice were not protected from colitis. These results indicate that in 
an animal model where antigen activated T cells are required for 
colitis induction the presence of ILC is irrelevant for the outcome 
of colitis. In line with this idea, using a T cell independent model 
of colitis, we showed that mice were fully protected from colitis in 
the absence of IFNγ (Rag1−/− Ifnγ−/− mice) or in the absence of ILC 
(anti-Thy1.2 depleted Rag1−/− mice or Rag2−/− RorcGFP/GFP mice), 
in agreement with previous studies (20, 39). These results indicate 
that while IFNγ is redundant in a T cell model of colitis, IFNγ is 
absolutely required for T cell independent disease development 
in the anti-CD40 mouse model of colitis where also the absence 
of IFNγ cannot be compensated by IL17.
Furthermore, these data also corroborate the concept that 
mouse T  cells and ILC show overlapping functions in infec-
tion and inflammation (40) where in the presence of adaptive 
T cells the critical contributions of ILC seen in adaptive immune 
cell-deficient mice may not be further evident. This has been 
recently demonstrated also for the relevance of IL22-producing 
ILC3 in the protection against colonic infection with Citrobacter 
rodentium. In this model, the requirement for NKp46+ ILC3 for 
protective immunity seen in C. rodentium infected Rag2−/− mice 
was not observed in C. rodentium infected immunocompetent 
mice, which were able to control C. rodentium infection in the 
colon even upon selective depletion of NKp46+ ILC3 (41).
In conclusion, we clearly reveal a distinct role of IFNγ for the 
development of intestinal inflammation in two different mouse 
models of colitis in the same mouse strain with the same microbial 
composition. In the absence of an adaptive T cell response, ILC-
derived IFNγ is essential for mediating intestinal inflammation. 
On the other hand, IFNγ is not required for intestinal inflam-
mation in the CD4 T cell transfer model, where in the absence 
of IFNγ production, the colitogenic CD4 T  cells preferentially 
differentiate into IL17 secreting cells. These data thus suggest that 
for an effective treatment of patients with IBD, not only IFNγ, but 
also IL17A/F activity needs to be targeted.
MaTerials anD MeThODs
Mice
C57BL/6 mice were purchased from Harlan (Horst, The 
Netherlands), Thy1.1 C57BL/6, Rag1−/− and Ifng−/− mice were 
obtained from the SwIMMr (University of Zurich, Switzerland). 
Rag1−/− mice were crossed to Ifng−/− mice to obtain Rag1−/− Ifng−/− 
double knockout mice. Rag2−/− RorcGFP/GFP mice were kindly 
provided by B. Becher (University of Zurich, Switzerland). Mice 
were maintained under specific pathogen-free conditions at the 
central animal facility of the Medical School of the University of 
Bern or at the Institute of Laboratory Animal Science, University 
of Zurich.
antibodies and Flow cytometry
Anti-mouse CD45RB (16A) antibody was purchased from BD 
Pharmingen (San Diego, CA, USA). CD25 (PC61) antibody was 
purchased from eBioscience (San Diego, CA, USA). Anti-mouse 
CD4 (RM4-5), CD3 (145-2C11), TCRαβ (H57-597), CD45 
(30-F11), IFNγ (XMG1.2), IL17A (clone TC11-18H10), TNFα 
(MP6-XT22), Thy1.2 (53-2.1), and Thy1.1 (OX-7) were pur-
chased from Biolegend. For intracellular staining dead cells were 
excluded using the LIVE/DEAD® fixable dead cell stain kit (blue) 
from Invitrogen. After washing and surface staining, intracellular 
cytokine staining was performed using the FoxP3 staining kit 
from eBioscience. Biotinylated anti-mouse CD8α (53-6.7) and 
B220 antibodies were purified from hybridoma supernatants. 
Cells were acquired on a LSRII SORP (BD Biosciences, San 
Diego, CA, USA) and analyzed using FlowJo software (Tree Star, 
Ashland, OR, USA).
colitis Models
Anti-CD40-Mediated Colitis
Mice were injected i.p. with the anti-CD40 monoclonal antibody 
(clone FGK45, BioXcell; 150μg/mouse). After antibody injection, 
mice were observed daily and sacrificed after 5 days for subse-
quent immunological and histopathological analyses.
T Cell Transfer Colitis
T  cell transfer colitis was performed as described previously 
with minor modifications (42). Splenocytes from C57BL/6, 
Thy1.1 C57BL/6 or Ifng−/− mice were enriched for CD4 T cells 
by MACS-depletion of CD8 and B220 cells (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Enriched CD4 T cells were then 
sorted on a FACS Aria Cell Sorter (Becton Dickinson, San Jose, 
CA, USA) to obtain CD4 CD25−CD45RBhi T  cells. Rag1−/−, 
Rag1−/− Ifng−/−, and Rag2−/− RorcGFP/GFP mice were injected i.p. with 
2 × 105 sort-purified CD4 CD25-CD45RBhi T cells. For depletion 
of ILC, Thy1.2+ recipients of Thy1.1+ CD4 T cells were injected 
with anti-Thy1.2 depleting antibodies i.p. [clone 30H12, 500 μg/
mouse (BioXcell, West Lebanon, NH, USA)]. For targeting IL17 
responses in vivo, mice were injected twice a week i.p. with neu-
tralizing antibodies against IL17A and IL17F for the duration of 
the experiment (anti-IL17A clone 17F3, 250 μg/mouse (BioXcell, 
West Lebanon, USA), anti-IL17F (L31409-098), 250 μg/mouse 
kindly provided by Pfizer). All animals were monitored regularly 
for weight loss and normal activity and sacrificed at the onset 
of clinical signs of colitis (defined by weight loss ≥15% and/or 
diarrhea for ≥24 time; altered behavior for ≥48 time; or bloody 
stool) at 24–28 days post disease induction.
histopathological assessment
Intestinal tissue specimens from the colon were fixed in 
4% paraformaldehyde for subsequent paraffin embedding. 
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Deparaffinized tissue sections were stained with hematoxylin and 
eosin for histological scoring based on the following parameters: 
(1) infiltration of the LP of the large bowel (score from 0 to 3), (2) 
mucin depletion/loss of goblet cells (score from 0 to 3), (3) crypt 
abscesses (score from 0 to 3), (4) epithelial erosion (score from 0 
to 1), (5) hyperemia (score from 0 to 2), and (6) thickness of the 
colonic mucosa (score from 0 to 3). Hence, the histopathological 
score ranges from 0 (no alteration) to 15 (most severe signs of 
colitis). Histological scoring was performed by a pathologist (VG) 
blinded to sample identity.
cell isolation
Colonic LP cells were isolated as described previously with 
minor modifications (43). Briefly, tissues were placed in Ca2+ 
and Mg2+-free Hanks’ balanced salt solution (HBSS) containing 
10 mM Hepes, 2% horse serum (HS), 0.5 mM EDTA, and 2 mM 
DTT at 37°C for 30 min to detach epithelial cells, followed by 
30′–45′ incubation HBSS/HEPES buffer containing 5% HS and 
100 U/ml collagenase type IV (Sigma, St. Louis, MO, USA) and 
50 U/ml DNase (type I, grade II; Roche) at 37°C. Isolated cells 
from the LP were then passed through a 70 µm cell strainer for 
subsequent counting and FACS analysis. Cells from mesenteric 
and caudal lymph nodes and spleen were isolated by squeezing 
the organs through a 40  µm cell strainer. Blood samples were 
collected from the tail vein (or the heart on days of analysis) 
into PBS containing 10 mM EDTA and 5% HS. Erythrocytes in 
blood samples and spleens were lysed using ACK lysis buffer. 
Cells were subsequently counted and stained for flow cytometric 
analyses. Absolute cell numbers were calculated based on the 
relative frequency of particular cell subsets and total number 
of viable cells in the respective lymphoid compartment. Results 
were plotted using GraphPad Prism (GraphPad Software, La 
Jolla, CA, USA).
cell culture and re-stimulations
Cells isolated from the LP, spleen, and mesenteric lymph nodes 
were cultured in 96-well U-bottom plates at 37°C, 5% CO2 in 
Iscove’s modified Dulbecco’s Medium (IMDM) containing 10% 
fetal calf serum (FCS) and 5 mM glutamine. Cells were stimulated 
with PMA (20 ng/ml, Sigma, St. Louis, MO, USA) and ionomycin 
(2 µg/ml, Sigma, St. Louis, MO, USA) for 5 h. After 2 h of culture, 
brefeldin A (10 µg/ml, Sigma, St. Louis, MO, USA) was added 
to the culture. After 5 h, cells were harvested and FACS stained. 
To exclude dead cells, the LIVE/DEAD® fixable dye was applied 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
manual. Subsequently, cells were surface stained followed by 
intracellular cytokine staining using the FoxP3 staining kit from 
(eBioscience, San Diego, CA, USA).
For in vitro priming of naïve CD4 T cells, sort-purified CD4 
CD45RBhi T  cells were cultured in IMDM medium (10% FCS, 
5  mM glutamine) for 8  days under Th17 priming conditions: 
rmIL6 (40  ng/ml), rhTGFβ (6  ng/ml), rmIL23 (20  ng/ml) on 
anti-CD3/anti-CD28 coated plates (1 mg/ml) in the presence of 
neutralizing antibodies [anti-IL4 (10 µg/ml), anti-IFNγ (20 µg/
ml), or IFNγ (10  ng/ml)]. All cytokines were purchased from 
Peprotech (Hamburg, Germany).
rna isolation, cDna synthesis, and  
qrT-Pcr
Whole tissues were preserved in RNA-later (Ambion, MA, USA) 
and sort-purified CD4 T cells in TRI-reagent and stored at −80°C 
until RNA isolation. RNA was isolated using TRI-reagent accord-
ing to the manufacturer’s instructions (Molecular Research 
Centre, Cincinnati, OH, USA). Genomic DNA was digested with 
DNase I (Sigma), and cDNA was generated with the Superscript 
II kit (Applied Biosystems, Muttenz, Switzerland). Samples 
were run on an Applied Biosystems 7500 Real-time PCR system 
with Quantitect Primer Assays (Qiagen, Düsseldorf, Germany). 
Results were normalized using the ΔΔ cycle threshold method 
relative to the housekeeping gene Gapdh.
statistical analysis
All data were analyzed and plotted using Graphpad Prism 6 
and results are depicted as mean ±  SD. Statistical analysis was 
performed as described in the figure legends. In general, the two-
tailed Mann–Whitney t-test was used to compare two groups. 
One-way ANOVA with Tukey’s multiple or Dunn’s multiple 
comparison test was used when three or more groups were com-
pared with each other. Results were considered significant with 
*P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001.
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Swiss laws and with the approval by the animal experimentation 
committee of the County of Bern under the protocol number 
BE119/11 and 125/14.
aUThOr cOnTriBUTiOns
CM and JB designed the study. JB performed most of the experi-
ments while CKC, DZ, NH-D, and NC contributed to the experi-
mental work, and together with JB, MN, and CM analyzed and 
discussed the experimental data and provided conceptual advice. 
VG performed the histopathology scoring of intestinal tissue sec-
tions. CM supervised the work and together with JB, NC, MN, 
and CC wrote the manuscript. All authors were involved in the 
critical editing of the manuscript.
acKnOWleDgMenTs
We thank all the members of the Mueller laboratory for discus-
sions and are grateful for the technical advice and support 
obtained from the Center for Flow Cytometry and Cell Sorting 
Resources of the Department of Biomedical Research, University 
of Bern. We would like to thank Pfizer for kindly providing the 
anti-IL17F neutralizing antibody.
FUnDing
This work was supported by the Swiss National Science Foundation 
SNSF grant no. 31-138392 and 170084 to CM.
11
Brasseit et al. IFNγ: Divergent Roles in Colitis
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 23
reFerences
1. de Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. 
Nat Rev Gastroenterol Hepatol (2016) 13:13–27. doi:10.1038/nrgastro.2015.186 
2. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflam-
matory bowel diseases. Gastroenterology (2011) 140:1756–67. doi:10.1053/j.
gastro.2011.02.016 
3. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition 
of Th1 responses prevents inflammatory bowel disease in SCID mice 
reconstituted with CD45RBhi CD4+ T  cells. Immunity (1994) 1:553–62. 
doi:10.1016/1074-7613(94)90045-0 
4. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, et  al. 
Interferon-gamma is causatively involved in experimental inflam-
matory bowel disease in mice. Clin Exp Immunol (2006) 146:330–8. 
doi:10.1111/j.1365-2249.2006.03214.x 
5. Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et  al. 
Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- 
and IL-15-responsive IFN-γ-producing cells. Immunity (2013) 38:769–81. 
doi:10.1016/j.immuni.2013.02.010 
6. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et  al. 
Interleukin-23 drives innate and T  cell-mediated intestinal inflammation. 
J Exp Med (2006) 203:2473–83. doi:10.1084/jem.20061099 
7. Muzaki AR, Tetlak P, Sheng J, Loh SC, Setiagani YA, Poidinger M, et  al. 
Intestinal CD103(+)CD11b(-) dendritic cells restrain colitis via IFN-γ-
induced anti-inflammatory response in epithelial cells. Mucosal Immunol 
(2016) 9:336–51. doi:10.1038/mi.2015.64 
8. Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. Fontolizumab 
in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, 
placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 16:233–42. 
doi:10.1002/ibd.21038 
9. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, et al. 
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and 
Crohn’s disease. Gut (2008) 57:1682–9. doi:10.1136/gut.2007.135053 
10. Geddes K, Rubino SJ, Magalhaes JG, Streutker C, Le Bourhis L, Cho JH, et al. 
Identification of an innate T helper type 17 response to intestinal bacterial 
pathogens. Nat Med (2011) 17:837–44. doi:10.1038/nm.2391 
11. Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, et al. 
Differential regulation of interleukin 17 and interferon gamma production 
in inflammatory bowel disease. Gut (2009) 58:1629–36. doi:10.1136/
gut.2009.182170 
12. Eken A, Singh AK, Treuting PM, Oukka M. IL-23R+ innate lymphoid cells 
induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol 
(2014) 7:143–54. doi:10.1038/mi.2013.33 
13. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, 
et  al. The orphan nuclear receptor RORgammat directs the differentiation 
program of proinflammatory IL-17+ T helper cells. Cell (2006) 126:1121–33. 
doi:10.1016/j.cell.2006.07.035 
14. Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C, et al. RORgamma-
expressing Th17  cells induce murine chronic intestinal inflammation via 
redundant effects of IL-17A and IL-17F. Gastroenterology (2009) 136:257–67. 
doi:10.1053/j.gastro.2008.10.018 
15. Griseri T, Arnold IC, Pearson C, Krausgruber T, Schiering C, Franchini F, et al. 
Granulocyte macrophage colony-stimulating factor-activated eosinophils 
promote interleukin-23 driven chronic colitis. Immunity (2015) 43:187–99. 
doi:10.1016/j.immuni.2015.07.008 
16. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, et al. 
Innate lymphoid cells drive interleukin-23-dependent innate intestinal 
pathology. Nature (2010) 464:1371–5. doi:10.1038/nature08949 
17. Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give 
rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad 
Sci U S A (2015) 112:7061–6. doi:10.1073/pnas.1415675112 
18. Rooks MG, Veiga P, Wardwell-Scott LH, Tickle T, Segata N, Michaud M, et al. 
Gut microbiome composition and function in experimental colitis during 
active disease and treatment-induced remission. ISME J (2014) 8:1403–17. 
doi:10.1038/ismej.2014.3 
19. Brasseit J, Althaus-Steiner E, Faderl M, Dickgreber N, Saurer L, Genitsch V, 
et  al. CD4 T  cells are required for both development and maintenance of 
disease in a new mouse model of reversible colitis. Mucosal Immunol (2016) 
9:689–701. doi:10.1038/mi.2015.93 
20. Vonarbourg C, Mortha A, Bui VL, Hernandez PP, Kiss EA, Hoyler T, et al. 
Regulated expression of nuclear receptor RORγt confers distinct functional 
fates to NK cell receptor-expressing RORγt(+) innate lymphocytes. Immunity 
(2010) 33:736–51. doi:10.1016/j.immuni.2010.10.017 
21. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, 
et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage dis-
tinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 6:1123–32. 
doi:10.1038/ni1254 
22. Fuss IJ, Neurath M, Boirivant M, Klein JS, la Motte de C, Strong SA, et al. 
Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflam-
matory bowel disease. Crohn’s disease LP cells manifest increased secretion of 
IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion 
of IL-5. J Immunol (1996) 157:1261–70. 
23. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, 
Iijima H, et al. The transcription factor T-bet regulates mucosal T cell activation 
in experimental colitis and Crohn’s disease. J Exp Med (2002) 195:1129–43. 
doi:10.1084/jem.20011956 
24. Simpson SJ, Shah S, Comiskey M, de Jong YP, Wang B, Mizoguchi E, et al. 
T  cell-mediated pathology in two models of experimental colitis depends 
predominantly on the interleukin 12/signal transducer and activator of 
transcription (Stat)-4 pathway, but is not conditional on interferon gamma 
expression by T  cells. J Exp Med (1998) 187:1225–34. doi:10.1084/jem.187. 
8.1225 
25. Wedebye Schmidt EG, Larsen HL, Kristensen NN, Poulsen SS, Lynge Pedersen 
AM, Claesson MH, et al. TH17 cell induction and effects of IL-17A and IL-17F 
blockade in experimental colitis. Inflamm Bowel Dis (2013) 19:1567–76. 
doi:10.1097/MIB.0b013e318286fa1c 
26. Krausgruber T, Schiering C, Adelmann K, Harrison OJ, Chomka A, 
Pearson C, et al. T-bet is a key modulator of IL-23-driven pathogenic CD4(+) 
T cell responses in the intestine. Nat Commun (2016) 7:11627. doi:10.1038/
ncomms11627 
27. O’Connor W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al. A 
protective function for interleukin 17A in T cell-mediated intestinal inflam-
mation. Nat Immunol (2009) 10:603–9. doi:10.1038/ni.1736 
28. Zimmermann J, Kühl AA, Weber M, Grün JR, Löffler J, Haftmann C, et al. 
T-bet expression by Th cells promotes type 1 inflammation but is dispensable 
for colitis. Mucosal Immunol (2016) 9:1487–99. doi:10.1038/mi.2016.5 
29. Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Gulan F, Cayatte C, et  al. 
Interleukin-23-independent IL-17 production regulates intestinal epithelial 
permeability. Immunity (2015) 43:727–38. doi:10.1016/j.immuni.2015.09.003 
30. Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et  al. 
Differential roles for interleukin-23 and interleukin-17 in intestinal immu-
noregulation. Immunity (2015) 43:739–50. doi:10.1016/j.immuni.2015.08.019 
31. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, 
Higgins PDR, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, 
for moderate to severe Crohn’s disease: unexpected results of a randomised, 
double-blind placebo-controlled trial. Gut (2012) 61:1693–700. doi:10.1136/
gutjnl-2011-301668 
32. Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. 
A randomized, double-blind, placebo-controlled phase 2 study of Brodalumab 
in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol 
(2016) 111:1599–607. doi:10.1038/ajg.2016.298 
33. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, 
et  al. A randomized trial of Ustekinumab, a human interleukin-12/23 
monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. 
Gastroenterology (2008) 135:1130–41. doi:10.1053/j.gastro.2008.07.014 
34. Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, 
Nikolov R, et al. Efficacy, safety and tolerability of vidofludimus in patients 
with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 
(2013) 7:636–43. doi:10.1016/j.crohns.2012.09.016 
35. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, et al. Either a Th17 
or a Th1 effector response can drive autoimmunity: conditions of disease 
induction affect dominant effector category. J Exp Med (2008) 205:799–810. 
doi:10.1084/jem.20071258 
36. Yeh W-I, McWilliams IL, Harrington LE. IFNγ inhibits Th17 differentiation 
and function via Tbet-dependent and Tbet-independent mechanisms. 
J Neuroimmunol (2014) 267:20–7. doi:10.1016/j.jneuroim.2013.12.001 
37. Kelchtermans H, Schurgers E, Geboes L, Mitera T, Van Damme J, Van Snick 
J, et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in 
12
Brasseit et al. IFNγ: Divergent Roles in Colitis
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 23
the absence of interferon-gamma and counteraction by interferon-gamma. 
Arthritis Res Ther (2009) 11:R122. doi:10.1186/ar2787 
38. Shen W, Hixon JA, McLean MH, Li WQ, Durum SK. IL-22-expressing murine 
lymphocytes display plasticity and pathogenicity in reporter mice. Front 
Immunol (2015) 6:662. doi:10.3389/fimmu.2015.00662 
39. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, 
Stepankova R, et al. Differential activity of IL-12 and IL-23 in mucosal and sys-
temic innate immune pathology. Immunity (2006) 25:309–18. doi:10.1016/j.
immuni.2006.05.017 
40. Bando JK, Colonna M. Innate lymphoid cell function in the context of adap-
tive immunity. Nat Immunol (2016) 17:783–9. doi:10.1038/ni.3484 
41. Rankin LC, Girard-Madoux MJH, Seillet C, Mielke LA, Kerdiles Y, Fenis A, 
et al. Complementarity and redundancy of IL-22-producing innate lymphoid 
cells. Nat Immunol (2016) 17:179–86. doi:10.1038/ni.3332 
42. Kwong Chung CK, Brasseit J, Althaus-Steiner E, Rihs S, Mueller C. Mouse 
model of reversible intestinal inflammation. Bio-protocol (2017) 7:1–11. 
doi:10.21769/BioProtoc.2173 
43. Corazza N, Eichenberger S, Eugster HP, Mueller C. Nonlymphocyte-derived 
tumor necrosis factor is required for induction of colitis in recombination 
activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) 
T cells. J Exp Med (1999) 190:1479–92. doi:10.1084/jem.190.10.1479 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Brasseit, Kwong Chung, Noti, Zysset, Hoheisel-Dickgreber, 
Genitsch, Corazza and Mueller. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
